Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal
cells. This may be an effective treatment for chronic lymphocytic leukemia (CLL),
prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL that has not responded to
chemotherapy, surgery or radiation therapy.
PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015
immunotoxin in treating patients who have chronic lymphocytic leukemia, prolymphocytic
leukemia or small lymphocytic lymphoma that has not responded to treatment